Chemotherapy-induced Parkinsonism responsive to levodopa: An underrecognized entity

Movement Disorders

Volumn 18, Issue 3, 2003, Pages 328-331

  Chuang, Cathy ^a   Constantino, Anne ^a   Balmaceda, Casilda ^a   Eidelberg, David ^b   Frucht, Steven J ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Chemotherapy; Levodopa; Pakinsonism

Indexed keywords

6 FLUORODOPA; ALPHA INTERFERON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BUSULFAN; CAPECITABINE; CARBIDOPA PLUS LEVODOPA; CARBOPLATIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOPAMINE RECEPTOR BLOCKING AGENT; FLUORODEOXYGLUCOSE; FUROSEMIDE; GEMCITABINE; HYDROXYUREA; LEVODOPA; LEVOFLOXACIN; LORAZEPAM; NAVELBINE; NEUROLEPTIC AGENT; NIFEDIPINE; ONDANSETRON; PACLITAXEL; PREDNISONE; TAMOXIFEN; TEMAZEPAM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARM EDEMA; ARTICLE; BODY POSTURE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSPHAGIA; FEMALE; HUMAN; HYPERTENSION; LUNG FIBROSIS; MASTECTOMY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PNEUMONIA; PRIORITY JOURNAL; REFLEX DISORDER; REMISSION; SINUSITIS; SLEEP DISORDER; SPEECH DISORDER; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION;

AGED; ANTINEOPLASTIC AGENTS; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MIDDLE AGED; PARKINSONIAN DISORDERS; TREATMENT OUTCOME;

EID: 0037355926     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10344     Document Type: Article

References (17)

1. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used anti-neoplastic agents (first of two parts). N Engl J Med 1974;291:75-81.
2. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used anti-neoplastic agents (second of two parts). N Engl J Med 1974;291:127-133.
3. Abelson HT. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978;62:1999-2001.
4. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191-214.
5. Luque FA, Selhorst JB, Petruska P. Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 1987;2:219-222.
6. Fleming DR, Mangino PB. Parkinsonian syndrome in a dialysis-supported patient receiving high dose chemotherapy for multiple myeloma. South Med J 1997;90:364-365.
7. Mott SH, Packer RJ, Vezina LG, Kapur S, Dinndorf PA, Conry JA, Pranzatelli MR, Quinones RR. Encephalopathy with parkinsonian features in children following bone marrow transplantation and high-dose amphotericin B. Ann Neurol 1995;37:810-814.
8. Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol 1991;7:457-463.
9. Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994;10:131-140.
10. Kulkantrakorn K, Selhorst JB, Petruska PJ. Cytosine arabinoside and amphotericin B-induced parkinsonism. Ann Neurol 1996;39:413-414.
11. Bergevin PR, Patwardhan VC, Weissman J, Lee SM. Neurotoxicity of 5-fluorouracil. Lancet 1975;1:410.
12. Boranic M, Raci F. A parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukemia. Biomedicine 1979;31:124-125.
13. Howell SJL, Sagar HJ. A progressive parkinsonian syndrome developing after chemotherapy and radiotherapy for non-Hodgkin's lymphoma. Mov Disord 1994;9:373-374.
14. Merello M, Esteguy M, Perazzo F, Leiguarda R. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol 1992;15:69-74.
15. Linn M, Brodt E, Gutschow K, Kolben M. Progression of Parkinson's disease with impairment of vision under carboplatin/cyclophosphamide therapy for ovarian cancer. Cancer Chemother Pharmacol 1998;41:427-428.
16. Bower JH, Muenter MD. Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma. Mov Disord 1995;10:681-682.
17. Mira Portugal MT, Vara F, Morales V, Sanchez-Prieto J, Santos Ruiz A, Arias J, Estabanez E, Gil JL, Duran Sacristan H. Decrease in human plasma dopamine-beta hydroxylase levels with vinca alkaloid treatment. Biomedicine 1978;29:306-308.